The third primary endpoint of time‐to‐first cardiovascular death or heart failure hospitalization in patients with transferrin saturation <20% occurred in 81 men in the treatment group compared with 113 in the placebo group (HR 0.73; 95% CI 0.55–0.97, p = 0.028). The gene discussed is TF; the disease is heart failure.